Cargando…

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study

BACKGROUND: Continuous, subcutaneous (SC) levodopa/carbidopa infusion with ND0612 is under development as a treatment for patients with Parkinson's disease (PD) and motor fluctuations. OBJECTIVE: Evaluate 1‐year safety data. METHODS: BeyoND is an open‐label study evaluating the long‐term safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poewe, Werner, Stocchi, Fabrizio, Arkadir, David, Ebersbach, Georg, Ellenbogen, Aaron L., Giladi, Nir, Isaacson, Stuart H., Kieburtz, Karl, LeWitt, Peter, Olanow, C. Warren, Simuni, Tanya, Thomas, Astrid, Zlotogorski, Abraham, Adar, Liat, Case, Ryan, Oren, Sheila, Fuchs Orenbach, Shir, Rosenfeld, Olivia, Sasson, Nissim, Yardeni, Tami, Espay, Alberto J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291977/ https://www.ncbi.nlm.nih.gov/pubmed/34496081 http://dx.doi.org/10.1002/mds.28758

Ejemplares similares

Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study
por: Olanow, C. Warren, et al.
Publicado: (2021)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
por: LeWitt, Peter A., et al.
Publicado: (2022)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

Stabile Levodopa-Spiegel durch subkutane Infusion von Foslevodopa/Foscarbidopa
por: Ebersbach, Georg
Publicado: (2021)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

The Clinical Development of Levodopa Inhalation Powder
por: Hauser, Robert A., et al.
Publicado: (2023)

Efficacy of Istradefylline, an Adenosine A(2A) Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
por: Hauser, Robert A., et al.
Publicado: (2021)

A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic
por: Kieburtz, Karl, et al.
Publicado: (2020)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Poewe, Werner, et al.
Publicado: (2010)

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
por: McGarry, Andrew, et al.
Publicado: (2020)

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease
por: LeWitt, Peter A., et al.
Publicado: (2018)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson’s Disease patients assessed using pseudo-continuous arterial spin labeling
por: Chen, Yufen, et al.
Publicado: (2015)

Levodopa-responsive dystonia caused by biallelic PRKN exon inversion invisible to exome sequencing
por: Mor-Shaked, Hagar, et al.
Publicado: (2021)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
por: LeWitt, Peter A., et al.
Publicado: (2012)

Diffuse Facial Hyperpigmentation as a Presenting Sign of Lupus Erythematosus: Three Cases and Review of the Literature
por: Azrielant, Shir, et al.
Publicado: (2021)

Subjective Visual Vertical in PD Patients with Lateral Trunk Flexion
por: Gandor, F., et al.
Publicado: (2016)

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2018)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy
por: Espay, Alberto J., et al.
Publicado: (2017)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo(®) 200) in the treatment of Parkinson’s disease: a case series
por: Sethi, Kapil D, et al.
Publicado: (2009)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Levodopa-Induced Pseudopheochromocytoma
por: Cardoso, Joana, et al.
Publicado: (2023)

Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials
por: Lang, Anthony E., et al.
Publicado: (2015)

Levodopa-induced respiratory dysfunction confirmed by levodopa challenge test: A case report
por: Ko, Pan-Woo, et al.
Publicado: (2018)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jqj8n82g1po1f7kscglk3rrnu2